Anebulo doses first patient in Phase 2 study of ANEB-001 for acute cannabinoid intoxication; expects topline in 1H 2022

Anebulo Pharmaceuticals, Inc.

First patient dosed in Phase 2 proof-of-concept study evaluating ANEB-001 for acute cannabinoid intoxication.
Part A will enroll 60 patients randomized 1:1:1 to 50mg, 100mg ANEB-001 or placebo, all receiving 10.5mg THC challenge.
Initial topline results from Part A expected in first half of 2022.
FDA pre-IND meeting provided guidance; Anebulo expects to submit IND in Q1 2022.
FDA accepted a THC challenge model for efficacy; company plans MIDD paired-meeting request.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.